Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M87,040Revenue $M16,385Net Margin (%)16.6Z-Score5.3
Enterprise Value $M87,654EPS $1.5Operating Margin %17.5F-Score6
P/E(ttm))32.5Cash Flow Per Share $2.8Pre-tax Margin (%)19.3Higher ROA y-yY
Price/Book5.710-y EBITDA Growth Rate %0.7Quick Ratio1.6Cash flow > EarningsY
Price/Sales5.45-y EBITDA Growth Rate %-13.3Current Ratio1.8Lower Leverage y-yN
Price/Cash Flow11.7y-y EBITDA Growth Rate %168ROA % (ttm)7.5Higher Current Ratio y-yY
Dividend Yield %2.8Insider Buy (3m)0ROE % (ttm)17.9Less Shares Outstanding y-yN
Payout Ratio %89.0Shares Outstanding M1,658ROI % (ttm)5.7Gross Margin Increase y-yN

Gurus Latest Trades with BMY

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BMYVanguard Health Care Fund 2014-06-30 Add0.86%$46.59 - $52.19
($49.29)
$ 51.845%Add 22.96%36,197,961
BMYJoel Greenblatt 2014-06-30 Buy 0.05%$46.59 - $52.19
($49.29)
$ 51.845%New holding, 89363 sh.89,363
BMYKen Fisher 2014-06-30 Add$46.59 - $52.19
($49.29)
$ 51.845%Add 216.1%49,732
BMYRay Dalio 2014-06-30 Sold Out $46.59 - $52.19
($49.29)
$ 51.845%Sold Out0
BMYRonald Muhlenkamp 2014-03-31 Buy 1.9%$48.54 - $56.61
($53.23)
$ 51.84-3%New holding, 212015 sh.212,015
BMYVanguard Health Care Fund 2014-03-31 Add0.73%$48.54 - $56.61
($53.21)
$ 51.84-3%Add 20.35%29,437,761
BMYRay Dalio 2014-03-31 Buy $48.54 - $56.61
($53.23)
$ 51.84-3%New holding, 4428 sh.4,428
BMYGeorge Soros 2014-03-31 Sold Out -0.05%$48.54 - $56.61
($53.23)
$ 51.84-3%Sold Out0
BMYJoel Greenblatt 2014-03-31 Sold Out -0.02%$48.54 - $56.61
($53.23)
$ 51.84-3%Sold Out0
BMYJoel Greenblatt 2013-12-31 Buy 0.02%$46.41 - $53.84
($50.96)
$ 51.842%New holding, 11679 sh.11,679
BMYVanguard Health Care Fund 2013-09-30 Add0.64%$41.32 - $47.53
($43.84)
$ 51.8418%Add 20.26%24,459,861
BMYIrving Kahn 2013-09-30 Reduce-0.19%$41.32 - $47.53
($43.84)
$ 51.8418%Reduce -48.95%28,300
BMYJean-Marie Eveillard 2013-09-30 Reduce-0.01%$41.32 - $47.53
($43.84)
$ 51.8418%Reduce -75.17%16,520
BMYVanguard Health Care Fund 2013-06-30 Add0.39%$39.68 - $47.68
($43.41)
$ 51.8419%Add 13.32%20,338,461
BMYGeorge Soros 2013-06-30 Buy 0.05%$39.68 - $47.68
($43.41)
$ 51.8419%New holding, 100000 sh.100,000
BMYJean-Marie Eveillard 2013-06-30 Add0.01%$39.68 - $47.68
($43.41)
$ 51.8419%Add 302.66%66,520
BMYIrving Kahn 2013-06-30 Reduce-2.17%$39.68 - $47.68
($43.41)
$ 51.8419%Reduce -86.62%55,433
BMYRay Dalio 2013-06-30 Sold Out -0.07%$39.68 - $47.68
($43.41)
$ 51.8419%Sold Out0
BMYPrem Watsa 2013-06-30 Sold Out -0.01%$39.68 - $47.68
($43.41)
$ 51.8419%Sold Out0
BMYVanguard Health Care Fund 2013-03-31 Add0.96%$32.59 - $41.19
($36.62)
$ 51.8442%Add 49.53%17,948,561
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BMY is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
BMY Brian Rogers 2014-09-306,264,8000.381.2+3.3%
BMY Joel Greenblatt 2014-06-3089,3630.010.05New Buy
BMY Ken Fisher 2014-06-3049,73200.01+216.1%
BMY Vanguard Health Care Fund 2014-06-3036,197,9612.184.6+22.96%
BMY Brian Rogers 2014-06-306,064,8000.371+3.41%
BMY Ronald Muhlenkamp 2014-06-30212,7700.011.8+0.36%
BMY Dodge & Cox 2014-06-3078,92100-0.25%
BMY Mario Gabelli 2014-06-30674,6850.040.17-1.76%
BMY Irving Kahn 2014-06-3027,65000.2-6.75%
BMY Jean-Marie Eveillard 2014-06-3014,49200-12.28%
BMY Ray Dalio 2014-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


BMY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
CORNELIUS JAMES MDirector 2014-10-15Sell100,000$48.925.93view
ANDREOTTI LAMBERTOCEO 2014-10-06Sell50,000$50.991.63view
Cuss Francis MEVP & CSO 2014-09-16Sell63,667$50.772.07view
Caforio GiovanniCOO 2014-09-15Sell26,691$49.873.91view
Caldarella Joseph CSVP & Controller 2014-09-10Sell7,415$51.031.55view
ANDREOTTI LAMBERTOCEO 2014-09-08Sell50,000$51.051.51view
von Autenried PaulSVP, Enterp. Services & CIO 2014-08-19Sell20,000$49.893.87view
Bancroft Charles AEVP & CFO 2014-07-29Sell67,621$51.061.49view
Moed Samuel JSVP, Strat Plan & Analysis 2014-07-28Sell25,752$49.325.07view
Caldarella Joseph CSVP & Controller 2014-03-13Sell9,137$55.2-6.12view

Press Releases about BMY :

Quarterly/Annual Reports about BMY:

News about BMY:

Articles On GuruFocus.com
Weekly CFO Sells Highlight: Williams Companies Inc, Google Inc, Bristol-Myers Squibb Company Oct 19 2014 
The Six Types of Winning Stocks Oct 17 2014 
Bristol-Myers: Absolute Valuation Model versus Relative Valuation Model Aug 29 2014 
Will ImmunoGen’s Q4 Earnings Disappoint Again? Jul 30 2014 
UnitedHealth Group Up on Weak Day for the Dow Jul 17 2014 
Pharma Sector Stocks To Consider For Sustained Returns Jun 25 2014 
Johnson & Johnson (JNJ) Dividend Stock Analysis May 29 2014 
A Look at AstraZeneca’s New Drug on Diabetes May 22 2014 
Vanguard Health Care Fund's Top Quarterly Holdings Apr 30 2014 
Abbvie Inc. (ABBV) Dividend Stock Analysis Mar 21 2014 

More From Our Partners
Big Pharma firms prevail in whistleblower suit Oct 20 2014 - SEEKINGALPHA

More From Other Websites
AstraZeneca, Bristol-Myers Won’t Face Kickback Lawsuit Oct 20 2014
Cramer: Tune in for the most vital earnings week Oct 17 2014
Next week's earnings: Tech takes center stage Oct 17 2014
Roche, Merck extend immunotherapy fight to breast cancer Oct 17 2014
AbbVie Kills Shire Merger, But Door Opens for Bristol-Myers Squibb? Oct 16 2014
How Will Bristol-Myers Squibb (BMY) Stock React Today to This Upgrade? Oct 16 2014
Bristol-Myers Collaborates for Opdivo-Imbruvica Combo Oct 14 2014
Bristol-Myers Squibb to Hold Investor Teleconference to Discuss CMSTO Highlights Oct 13 2014
Bristol-Myers Squibb, Pharmacyclics and Janssen Announce Clinical Collaboration to Evaluate OPDIVO®... Oct 13 2014
BUZZ-Innate Pharma: Citi lauds French biotech firm's cancer work Oct 09 2014
Bristol-Myers Gives Up on US Approval of 2-Drug HCV Combo Oct 08 2014
Bristol-Myers Squibb Statement on Sustiva (efavirenz) in the U.S. Oct 08 2014
Cramer: Trust the Bristol-Myers Theorem Oct 08 2014
[$$] Bristol-Myers Drops Hepatitis C Dual Regimen in U.S. Oct 08 2014
Why Bristol-Myers Squibb (BMY) Stock Declined Today Oct 07 2014
Novartis Collaborates with Bristol-Myers Squibb Oct 07 2014
Bristol-Myers Pulls FDA Filing For 2-Drug Hep C Combo Oct 07 2014
UPDATE 1-Bristol-Myers pulls U.S. marketing application for hepatitis C treatment Oct 07 2014
Bristol-Myers Gives Up on Hepatitis C Combination in U.S. Oct 07 2014
Bristol-Myers pulls U.S. marketing application for hepatitis C treatment Oct 07 2014

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK